Arcus Biosciences, Inc. Common Stock, Capital Shares Reserved for Future Issuance
Arcus Biosciences, Inc. (RCUS) had Common Stock, Capital Shares Reserved for Future Issuance of 8.31 million shares as of 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2020-03-05
- 2019-12-31: Common Stock, Capital Shares Reserved for Future Issuance 8.31M shares.
- 2018-12-31: Common Stock, Capital Shares Reserved for Future Issuance 5.26M shares.
- 2017-12-31: Common Stock, Capital Shares Reserved for Future Issuance 32.86M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2019-12-31 | 8.31M shares 10-K · filed 2020-03-05 |
| 2018-12-31 | 5.26M shares 10-K · filed 2020-03-05 |
| 2017-12-31 | 32.86M shares 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |